---
title: "Why Is NervGen Pharma Stock Gaining Tuesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287636837.md"
description: "NervGen Pharma's stock (NGEN) rose 5.29% after announcing a 100% responder rate for its NVG-291 treatment in spinal cord injury gait analysis from the Phase 1b/2a CONNECT SCI study. The company plans to initiate a Phase 3 study in mid-2026, with significant improvements in gait quality reported. The stock is currently trading at $2.19, still below key moving averages, with resistance at $3.65 and support at $1.98."
datetime: "2026-05-26T12:33:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287636837.md)
  - [en](https://longbridge.com/en/news/287636837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287636837.md)
generator: "portal-rs"
---

# Why Is NervGen Pharma Stock Gaining Tuesday?

**NervGen Pharma Corp**. (NASDAQ:NGEN) stock is trading higher Tuesday morning after the clinical-stage biopharmaceutical company announced positive independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study.

## Genuine Neural Recovery Demonstrated

The Vancouver-based company reported that its lead therapeutic candidate, NVG-291, demonstrated a statistically significant improvement in gait quality (p=0.0197) for chronic spinal cord injury patients.

The analyses, conducted by AI-powered movement intelligence company Newton Tech on Tuesday, focused on three established hallmarks of true neural repair: coordination, mechanical effort and postural stability.

## Perfect Responder Rate Highlights Data

According to the Global Statistical Test used in the study, 100% (10 out of 10) of the subjects treated with NVG-291 were classified as responders across the composite recovery measures. In comparison, only 10% (1 out of 10) of the placebo group qualified as responders (p=0.0001).

“The multi-domain biomechanical signature reported here is precisely the pattern one would hope to find from a therapy enabling true underlying neural recovery,” stated **Armin Curt**, Clinical Director of the SCI Center at **Balgrist University Hospital**.

NervGen CEO **Adam Rogers** noted Tuesday that these findings “further reinforce the foundation upon which we are advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia.” The company remains on track to initiate the Phase 3 study in mid-2026.

## NGEN Stock: Key Levels and Momentum Indicators

At $2.16, the stock is trading 40.8% below its 20-day SMA ($3.65), 44% below its 50-day SMA ($3.86), and 44.6% below its 100-day SMA ($3.90), which keeps overhead supply in focus on any rally.

The more constructive datapoint is the longer-term reference: the stock is trading 9.3% above its 200-day SMA ($1.98), so the $2 area is acting like a line in the sand that bulls want to defend.

The moving-average stack is still mixed, with the 20-day SMA below the 50-day SMA (bearish), but the 50-day SMA remains above the 200-day SMA, which is a longer-term positive if price can reclaim the shorter averages.

-   **Key Resistance**: $3.65 — the 20-day SMA is the nearest overhead trend level and a logical first test if the rebound extends
-   **Key Support**: $1.98 — the 200-day SMA sits just below current price and lines up with the broader $2 pivot zone

**NGEN Price Action:** NervGen Pharma shares were up 5.29% at $2.19 during premarket trading on Tuesday, according to Benzinga Pro data.

*Photo via Shutterstock*

### Related Stocks

- [NGEN.US](https://longbridge.com/en/quote/NGEN.US.md)

## Related News & Research

- [NervGen Prices $60 Mln Offering Of Shares And Warrants To Advance NVG-291; Stock Down](https://longbridge.com/en/news/287319498.md)
- [Matricelf says FDA backs key design elements for first-in-human NewRal spinal cord injury trial](https://longbridge.com/en/news/297917329.md)
- [06:00 ETNovaGo Therapeutics cierra una ronda de financiación para un estudio en lesiones agudas de la médula espinal](https://longbridge.com/en/news/297765618.md)
- [08:05 ETWisner Baum Named to Leadership in Federal Spinal Cord Stimulator Litigation](https://longbridge.com/en/news/297514089.md)
- [SRX Global buys senior secured debt in CERo Therapeutics Holdings](https://longbridge.com/en/news/297509635.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**